GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. It also has a large consumer healthcare division which produces and markets oral healthcare products, nutritional drinks and over-the-counter medicines, including Sensodyne, Horlicks and Gaviscon.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2010 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2013. may lag behind FEC section above, as donors and industries are identified by hand.
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of GlaxoSmithKline
Names of Lobbyists
Firm Hired Amount GlaxoSmithKline $14,830,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Government Issues,
- Foreign Relations,
Most Frequently Disclosed Bills
Bill No. Title S.515 Patent Reform Act of 2009 H.R.1260 Patent Reform Act of 2009 H.R.3590 Service Members Home Ownership Tax Act of 2009 S.610 Patent Reform Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.1548 Pathway for Biosimilars Act S.1679 Affordable Health Choices Act S.369 Preserve Access to Affordable Generics Act H.R.1 American Recovery and Reinvestment Act of 2009 S.1796 America's Healthy Future Act of 2009
RegulationsMentioned in 162 dockets; Submitted to 29 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "GlaxoSmithKline" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for GlaxoSmithKline
- Toggle 3 FDA FDA Transparency Task Force; Public Meeting 2009
- Toggle 2 FDA Draft Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products; Availability 2009
- Toggle 2 FDA Providing Effective Information to Consumers about Prescription Drug Risks and Benefits; Public Workshop 2009
- Toggle 1 FDA Investigational New Drug Applications; Co-Development of Investigational Drugs 2010
- Toggle 1 FDA Draft Guidance for Industry on Microbiology Data for Systemic Antibacterial Drug Products — Development, Analysis, and Presentation; Availability 2009
- Toggle 1 FDA Center for Drug Evaluation and Research Data Standards Plan; Availability for Comment. 2010
- Toggle 1 FDA Draft Guidance for Industry on Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment 2010
- Toggle 1 FDA Draft Guidance for Industry on Influenza: Developing Drugs for Treatment and/or Prophylaxis; Availability 2009
- Toggle 1 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 1 FDA Draft Guidance for Industry and Reviewers on SPL Standard for Content of Labeling Technical Qs & As, Revision 2009
Mentions in Document Text
View all mentions data for GlaxoSmithKline
- Toggle 486 FWS 90-Day Finding on a Petition To List All Chimpanzees (Pan troglodytes) as Endagered 2010
- Toggle 12 FDA Specific Legal and Scientific Requirements be Upheld in the Review of Proposed Generic Copies of Inhalation Products Containing Fluticasone Propionate and/or Salmeterol Xinafoate 2009
- Toggle 10 FDA Citizen Petition Concerning Generic Formulations of Coreg CR® А (Carvedilol Phosphate) Extended-Release Capsules 10mg, 20mg, 40mg and 80mg 2010
- Toggle 9 FDA Patent Term Extension Application for VOTRIENT® (pazopanib hydrochloride), U.S. Patent No. 7,105,530 2010
- Toggle 7 FDA Advisory Committee, Workshops, and Conferences Notices Various Meetings Notices (eg., Task Force Meeting, etc.) 2009
- Toggle 7 FDA Patent Term Extension Application for PROMACTA® (eltrombopag olamine), U.S. Patent No. 7,160,870) 2009
- Toggle 7 FDA FDA Transparency Task Force; Public Meeting 2009
- Toggle 6 FDA Determine Whether Augmentin, (Amoxicillin; Clavulanate Potassium) 200mg/5mL and 400 mg/5mL; NDA 50-725 Manufactured by GlaxoSmithKline has Been Voluntarily Withdrawn From Sale for Safety or Efficacy Reasons 2010
- Toggle 6 FDA Advisory Committee, Workshops, and Conferences Notices Various Meetings Notices (eg., Task Force Meeting, etc.) 2010
- Toggle 6 FDA Required Warnings for Cigarette Packages & Advertisements 2010
Contractor Misconduct10 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Health||None||Puerto Rico Drug Manufacturing Facility Settlement||2010||Pleaded Guilty||$750,000,000|
|Antitrust||None||Hawaii Average Wholesale Price Litigation||2010||Settlement||$10,000,000|
|Defective Pricing||None||Kentucky Kytril and Zofran Average Wholesale Price Lawsuit||2010||Settlement||$3,750,000|
|Health||None||Kilker v. SmithKline Beecham (Paxil Birth Defects)||2009||Judgment Against Defendant||$2,500,000|
|Health||None||Utah Attorney General Avandia Lawsuit||2010||Pending||$0|
|Health||None||FDA Review of Altabax Promotional Material||2010||Investigative Finding||$0|
|Health||None||Paxil Birth Defect Litigation||2010||Settlement||$0|
|Health||None||U.S. Senate Investigation of Avandia||2010||Investigative Finding||$0|
|Tax||None||Interest Payment Deduction Stemming from 2000 Merger||2009||Pending||$0|
|Health||None||Denture Cream Product Liability Litigation||2009||Settlement||$0|
Advisory Committees5 people on 5 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "GlaxoSmithKline" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 3 people on 3 committees
- Toggle Environmental Protection Agency 2 people on 2 committees